Clinical evidence evaluating the efficacy of rituximab in the treatment of wAIHA
| First author (year) . | Study type . | wAIHA type . | Setting . | Number of patients . | Age (years)* . | Previous Splx . | ORR/CRR . | Response duration . |
|---|---|---|---|---|---|---|---|---|
| Zecca (2003) | P | M | R/R | 14 | 0-14 | 13 | 87/NR | 7-27+ |
| Narat (2005) | R | M | R/R | 11 | 18-81 | 5 | 64/27 | 2-20 |
| D’Arena (2007) | R | PW | R/R | 11 | 23-81 | 9 | 100/73 | 1-96+ |
| Bussone (2009) | R | M | R/R | 27 | 15-81 | 22 | 93/30 | NR |
| Dierickx (2009) | R | M | R/R | 36 | 1-87 | 19 | 79/47 | 1-year PFS = 72% |
| Peñalver (2010) | R | M | R/R | 27 | 20-86 | 13 | 77/61 | 6+(if CR) |
| Barcellini (2013) | P | PW | F;R/R | 18 | 19-79 | 0 | 90/60 | 36+ |
| Maung (2013) | R | M | R/R | 34 | 14-83 | 3 | 71/26 | 6-60 |
| Birgens (2013) | P | M | F | 32 | 35-90 | 0 | 75% CR at 12 mo | 36+ |
| Roumier (2014) | R | M | R/R | 25 | 30-76 | NR | 80/NR | 50% relapse after 14 ± 8 months |
| Barcellini (2014) | R | PW | R/R | 32 | 0-95 | NR | 81/53 | NR |
| First author (year) . | Study type . | wAIHA type . | Setting . | Number of patients . | Age (years)* . | Previous Splx . | ORR/CRR . | Response duration . |
|---|---|---|---|---|---|---|---|---|
| Zecca (2003) | P | M | R/R | 14 | 0-14 | 13 | 87/NR | 7-27+ |
| Narat (2005) | R | M | R/R | 11 | 18-81 | 5 | 64/27 | 2-20 |
| D’Arena (2007) | R | PW | R/R | 11 | 23-81 | 9 | 100/73 | 1-96+ |
| Bussone (2009) | R | M | R/R | 27 | 15-81 | 22 | 93/30 | NR |
| Dierickx (2009) | R | M | R/R | 36 | 1-87 | 19 | 79/47 | 1-year PFS = 72% |
| Peñalver (2010) | R | M | R/R | 27 | 20-86 | 13 | 77/61 | 6+(if CR) |
| Barcellini (2013) | P | PW | F;R/R | 18 | 19-79 | 0 | 90/60 | 36+ |
| Maung (2013) | R | M | R/R | 34 | 14-83 | 3 | 71/26 | 6-60 |
| Birgens (2013) | P | M | F | 32 | 35-90 | 0 | 75% CR at 12 mo | 36+ |
| Roumier (2014) | R | M | R/R | 25 | 30-76 | NR | 80/NR | 50% relapse after 14 ± 8 months |
| Barcellini (2014) | R | PW | R/R | 32 | 0-95 | NR | 81/53 | NR |
This table excludes series describing the use of rituximab in patients with only secondary wAIHA. CR, compete response; CRR, complete response rate; F, frontline; M, mixed primary and secondary wAIHA; NR, not reported; ORR, overall response rate; P, prospective; PW, primary wAIHA; PFS, progression-free survival; R, retrospective; R/R, relapsed or refractory; splx, splenectomy; wAIHA, warm type autoimmune hemolytic anemia.
Age of all included patients (warm + cold type).